Huw Jones, chief executive of Evgen Pharma PLC AIM:EVG), stated that he expects to be able confirm the improved delivery of a new formulation of SFX-01. This is its key asset.
His comments were made along with an update on the status of sulforaphane drug treatment. It noted that all three cohorts of the placebo-controlled, dose-escalating randomised phase I/Ib trial had been completed.
The clinical evaluation will provide additional insight into the pharmacokinetics and pharmacodynamics of the new enteric coated tablet formulation of SFX-01.
Researchers are simultaneously investigating how sulforaphane from SFX-01 is released and how it interacts with molecular targets.
The data from the study are expected to be available in the second quarter, as previously mentioned.
To replace the original capsule formulation, the new tablet has been enteric-coated. The tablet releases sulforaphane (which is found in broccoli) to a specific part of the intestine with the goal of predictable release and minimisation side effects.
If the new formulation performs well, it will be suitable to commercial supply and large-scale trials.
Evgen CEO Jones stated that he anticipates that the new formulation will improve SFX-01 delivery. “It will also demonstrate how sulforaphane interacts with key molecular targets, as we expand into new indications for oncology or neurodevelopmental disorders.”
Post Disclaimer
The following content has been published by Stockmark.IT. All information utilised in the creation of this communication has been gathered from publicly available sources that we consider reliable. Nevertheless, we cannot guarantee the accuracy or completeness of this communication.
This communication is intended solely for informational purposes and should not be construed as an offer, recommendation, solicitation, inducement, or invitation by or on behalf of the Company or any affiliates to engage in any investment activities. The opinions and views expressed by the authors are their own and do not necessarily reflect those of the Company, its affiliates, or any other third party.
The services and products mentioned in this communication may not be suitable for all recipients, by continuing to read this website and its content you agree to the terms of this disclaimer.